clinical data, neuroscience

The group’s 7-2 ruling in favor of the therapeutic represents a shift from previous deliberations, in which data on its effectiveness was deemed insufficient.

The country’s provisional go-ahead could increase pressure already being exerted on the US Food and Drug Administration to approve the therapy.

The FDA pauses the research program on a lentivirus-based treatment for a rare neurological condition after a patient developed a bone marrow disorder that could presage leukemia.

A team of Stanford University researchers say that administering young people’s blood plasma to Alzheimer’s patients could improve cognitive function, but the results have been criticized.